DLK1‐directed chimeric antigen receptor T‐cell therapy for hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Liver International"
DOI: 10.1111/liv.15411
Abstract: Delta‐like homologue 1 (DLK1), a transmembrane protein, is highly expressed in hepatocellular carcinoma (HCC). We explored whether DLK1‐directed chimeric antigen receptor (CAR) T cells can specifically eliminate DLK1‐positive HCC cells and serve as a therapeutic… read more here.
Keywords: directed chimeric; hepatocellular carcinoma; antigen receptor; chimeric antigen ... See more keywords
Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0145
Abstract: Aim: Comprehensively characterize the cardiotoxicity of CD19-directed chimeric antigen receptor T-cell (CAR-T) products. Materials & methods: Data between 2017 and 2021 in the US FDA's Adverse Event Reporting System database were utilized. Disproportionality was measured using reporting… read more here.
Keywords: directed chimeric; antigen receptor; receptor cell; chimeric antigen ... See more keywords